In Vitro Evaluation of the Type of Interaction Obtained by the Combination of Terbinafine and Itraconazole, Voriconazole, or Amphotericin B against Dematiaceous Molds
In Vitro Evaluation of the Type of Interaction Obtained by the Combination of Terbinafine and Itraconazole, Voriconazole, or Amphotericin B against Dematiaceous Molds
复制标题
DOI：
10.1128/aac.01015-10
复制
发表时间：
2011-09-01
影响因子：
4.9
通讯作者：
Schreiber, Angelica Zaninelli
中科院分区：
文献类型：
--
作者：
Correa Biancalana, Fernanda Simas;Lyra, Luzia;Schreiber, Angelica Zaninelli
采用棋盘式微量稀释法的体外联合试验显示，联合应用的每种药物(特比奈芬、伊曲康唑、伏立康唑和两性霉素B)的最低抑菌浓度范围和最低抑菌浓度中位数均低于每种单一药物。分数抑制浓度指数(FIC)结果显示，特比奈芬与伏立康唑、两性霉素B、伊曲康唑的协同作用分别为100%、96.5%、75.9%。药物组合可能有助于治疗暗色霉菌感染，作为一种替代治疗方法，以提高每种药物的有效性。
In vitro associations using the checkerboard microdilution method indicated lower MIC ranges and MIC median values for each drug (terbinafine, itraconazole, voriconazole, and amphotericin B) in association than those obtained for each single drug. Fractional inhibitory concentration index (FIC) results showed 100% synergism in the association of terbinafine with voriconazole, 96.5% in the association of terbinafine with amphotericin B, and 75.9% in the association of terbinafine with itraconazole. Drug combinations may be useful for treatment of dematiaceous mold infections as an alternative treatment to enhance the effectiveness of each drug.